Compare S&P500 ETF (SPY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs Tango Therapeutics Inc. — how do they compare? S&P500 ETF trades at $766.8 (market cap $821.11B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: S&P500 ETF is far larger — about 219× Tango Therapeutics Inc.'s market cap, and S&P500 ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 206 Days and Tango Therapeutics Inc. for 0 Days on average.
| SPY | TNGX | |
|---|---|---|
Market Cap | $821.11B | $3.75B |
Volume | 25,825,560 | 9,619,106 |
52-Week High | $779.14 | $32.90 |
52-Week Low | $631.99 | $7.50 |
Typical Hold Time | 206 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY (SPDR S&P 500 ETF Trust) trades at $778.05, showing minimal daily movement with a slight decline of -0.02 (-0.0%). Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains its position as the primary S&P 500 tracking fund with upcoming dividend distribution scheduled for October 2026.
The ETF's outlook remains tied to broader market performance with Wall Street monitoring earnings growth projections. Key risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated market valuations. Current technical strength suggests near-term stability, but macroeconomic factors could drive volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
